Value-Based Care

Partner with policy experts

Our expertise and inter-disciplinary approach to value assessment frameworks offer incomparable custom solutions from a multi-stakeholder perspective. Whether you are looking for strategic market intelligence and access or leading policy experts, our consultants have direct pharmaceutical experience, strong payer relationships, and the knowledge to educate and advise senior leadership teams. 
Benefit from our expertise in value assessment frameworks
30
Vaf projects
15
strategic partnerships

Meet our experts

Kristen Migliaccio-Walle, BS

Kristen Migliaccio-Walle is Director of Global Health Economics & Outcomes Research Consulting at Xcenda. In this role, she conducts a broad range of global HEOR engagements including economic modeling, comparative effectiveness research and strategic HEOR assessment.
Kristen Migliaccio-Walle

Only 7 percent of employees said their company is ready to adapt to the product and quality information needed for new value-based pricing models. 

Value assessment frameworks

Some frameworks may undermine personalized medicine 

A new study authored by Xcenda finds that many value assessment frameworks still make sweeping conclusions about the economic worth of a treatment based almost exclusively on population averages. As a result, frameworks could unintentionally discourage payers and providers from considering important information about a patient’s biology and preferences that can improve health outcomes.
Read the white paper

Turn to Xcenda for global reach and local expertise

In light of growing competition for innovative therapies in addition to rising cost of treatments, manufacturers are pressured to demonstrate product value both clinically and economically. One leading payment model that has led such efforts to align with this objective is value-based pricing (VBP), in which financial risk is shared between manufacturers and payers. VBP has emerged as a front-runner in addressing product value by associating product prices with actual patient health outcomes. 
Start a conversation